TY - JOUR
T1 - The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing Auto-SCT
AU - Vangsted, A J
AU - Klausen, T W
AU - Ruminski, W
AU - Gimsing, P
AU - Andersen, Niels Frost
AU - Gang, A O
AU - Abildgaard, N
AU - Knudsen, L M
AU - Nielsen, Johan Lanng
AU - Gregersen, H
AU - Vogel, U
PY - 2009
Y1 - 2009
N2 - Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations leading to a modified expression of these cytokines will influence the outcome for these patients. We investigated 348 MM patients undergoing high-dose melphalan treatment followed by Auto-SCT and examined the influence of single nucleotide polymorphisms (SNPs) in genes involved in the inflammatory response. We found that the polymorphism IL-1beta T-31C significantly influenced overall survival (OS; P=0.02) and that carriers of the variant C-allele had a significantly longer survival than homozygous wild-type allele TT-carriers (relative risk 0.6 (95% CI=0.5-0.9); P=0.008). The polymorphisms IL-6 G-174C, IL-10 C592A, PPARgamma2 Pro(12)Ala, COX-2 A-1195G, COX-2 T8473C and NFKB1 ins/del did not influence the OS in this group of patients. Furthermore, homozygous carriers of the variant allele of IL-1beta T-31C were at 1.37-fold (CI=1.05-1.80) increased risk of MM as compared with population-based controls (P=0.02). Our results indicate that IL-1beta is involved in the pathogenesis of MM.Bone Marrow Transplantation advance online publication, 10 November 2008; doi:10.1038/bmt.2008.351.
AB - Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations leading to a modified expression of these cytokines will influence the outcome for these patients. We investigated 348 MM patients undergoing high-dose melphalan treatment followed by Auto-SCT and examined the influence of single nucleotide polymorphisms (SNPs) in genes involved in the inflammatory response. We found that the polymorphism IL-1beta T-31C significantly influenced overall survival (OS; P=0.02) and that carriers of the variant C-allele had a significantly longer survival than homozygous wild-type allele TT-carriers (relative risk 0.6 (95% CI=0.5-0.9); P=0.008). The polymorphisms IL-6 G-174C, IL-10 C592A, PPARgamma2 Pro(12)Ala, COX-2 A-1195G, COX-2 T8473C and NFKB1 ins/del did not influence the OS in this group of patients. Furthermore, homozygous carriers of the variant allele of IL-1beta T-31C were at 1.37-fold (CI=1.05-1.80) increased risk of MM as compared with population-based controls (P=0.02). Our results indicate that IL-1beta is involved in the pathogenesis of MM.Bone Marrow Transplantation advance online publication, 10 November 2008; doi:10.1038/bmt.2008.351.
U2 - 10.1038/bmt.2008.351
DO - 10.1038/bmt.2008.351
M3 - Journal article
SN - 0268-3369
VL - 43
SP - 539
EP - 545
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
ER -